Efetamol

Efetamol may be available in the countries listed below.

Ingredient matches for Efetamol

Paracetamol

Paracetamol is reported as an ingredient of Efetamol in the following countries:

• Spain

International Drug Name Search

Anturan

Anturan may be available in the countries listed below.

Ingredient matches for Anturan

Sulfinpyrazone

Sulfinpyrazone is reported as an ingredient of Anturan in the following countries:

• Ghana


• Guyana


• Israel


• Kenya


• Libya


• Nigeria


• Sudan


• Tanzania


• United Kingdom


• Zimbabwe

International Drug Name Search

D-Alfa

D-Alfa may be available in the countries listed below.

Ingredient matches for D-Alfa

Alfacalcidol

Alfacalcidol is reported as an ingredient of D-Alfa in the following countries:

• Japan

International Drug Name Search

Amicor

Amicor may be available in the countries listed below.

Ingredient matches for Amicor

Amrinone

Amrinone lactate (a derivative of Amrinone) is reported as an ingredient of Amicor in the following countries:

• India

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Amicor in the following countries:

• Croatia (Hrvatska)

Lisinopril

Lisinopril is reported as an ingredient of Amicor in the following countries:

• Croatia (Hrvatska)

International Drug Name Search

Farriers' Choice

Farriers' Choice may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Farriers' Choice

Chloroxylenol

Chloroxylenol is reported as an ingredient of Farriers' Choice in the following countries:

• Australia

International Drug Name Search

Ritemed Cefuroxime

Ritemed Cefuroxime may be available in the countries listed below.

Ingredient matches for Ritemed Cefuroxime

Cefuroxime

Cefuroxime sodium salt (a derivative of Cefuroxime) is reported as an ingredient of Ritemed Cefuroxime in the following countries:

• Philippines

International Drug Name Search

Demerol

Generic Name: Meperidine Hydrochloride
Class: Opiate Agonists
VA Class: CN101
CAS Number: 50-13-5

Introduction

Opiate agonist; a synthetic phenylpiperidine derivative.^b

Uses for Demerol

Acute Pain

A strong analgesic used in the relief of moderate to severe pain.^b

Usually, temporary relief of moderate to severe pain such as that associated with acute and some chronic medical disorders including renal or biliary colic, acute trauma, postoperative pain, and cancer.^e

Used to provide analgesia during diagnostic and orthopedic procedures and during labor.^{246 e}

For preoperative sedation and as a supplement to anesthesia.^e

Around-the-clock dosing of analgesics may be considered in the initial stages of acute pain to avoid wide swings in pain and sedation often associated with as-needed dosing regimens.^e

Although commonly used for acute pain relief, use as first-line opiate therapy is discouraged because of central excitatory toxicity of metabolite (normeperidine).^{247 245}

Because of extensive first-pass metabolism in the liver to normeperidine, the risk of excitatory toxicity is increased with oral administration of meperidine; therefore, oral therapy is discouraged.^{246 247 245}

Has been used to relieve the pain of MI, although probably not as effective as morphine sulfate.^b

Chronic Pain

Use for chronic pain is discouraged because of short duration of effect and risk of accumulation of normeperidine metabolite and resultant central excitatory toxicity with repeated or large doses.^{e 248}

Surgery

Used parenterally for preoperative sedation and as a supplement to anesthesia.^b

Pulmonary Edema

Used in patients with acute pulmonary edema† for its cardiovascular effects and to allay anxiety.^b

Do not use in the treatment of pulmonary edema resulting from a chemical respiratory irritant.^b

Demerol Dosage and Administration

General

• 
  

  Give the smallest effective dose and as infrequently as possible to minimize the development of tolerance and physical dependence.^b

  
  


• 
  

  Reduced dosage is indicated initially in poor-risk patients, in geriatric and very young patients, in patients with renal (particularly) or hepatic impairment, and in patients receiving other CNS depressants.^{b 246 247 245}

  
  


• 
  

  Reduce meperidine dose by 25–50% when used in conjunction with other CNS depressants (e.g., phenothiazines, other tranquilizers); dosage adjustment for the concomitantly administered drug also may be necessary.^b

  
  


• 
  

  Orally, 300 mg is approximately equianalgesic with 30 mg morphine sulfate.^{c 245 248} Parenterally, 75–100 mg is approximately equianalgesic with 10 mg morphine sulfate.^{c 245 248} (For specific patient dosages, see dosage recommendations in Dosage and also see Prescribing Limits under Dosage and Administration.)

  
  


• 
  

  Generally limit to short-term use (a few days) because of risk of accumulation of toxic normeperidine metabolite with repeated or large doses.^{e 247 245 248}

  
  

Administration

Administer orally; by sub-Q, IM, or slow IV injection; or by slow, continuous IV infusion.^b

Oral Administration

Least effective when given orally.^{b 246 247 245} Higher dosages may be necessary for pain relief, but the risk of toxicity from metabolite normeperidine is increased.^{247 248}

Oral therapy is discouraged because of extensive first-pass metabolism in the liver and resultant increased formation of the toxic metabolite (normeperidine).^{246 247 245 248}

Dilution

Dilute each dose of oral solution in ½ glassful of water, since undiluted solution may produce slight topical anesthesia on mucous membranes.^b

IV Administration

Administer by direct IV injection, IV infusion, or IV via a controlled-delivery device for patient-controlled analgesia (PCA).^{b c 246}

If IV administration is required, decrease dosage and administer injections very slowly, preferably as a 10-mg/mL injection.^{b HID}

Alternatively, may use the commercially available injection containing 10 mg/mL intended for use with a compatible infusion device (does not require further dilution); this 10-mg/mL injection is for single use only, and unused portions should be discarded appropriately.^b

When given parenterally, especially by the IV route, the patient should be lying down.^b

During and immediately following IV administration, an opiate antagonist and facilities for administration of oxygen and control of respiration should be available.^b

Dilution

May dilute in a compatible IV solution for infusion, usually to a concentration of 1 mg/mL.^{b HID} (See Solution Compatibility under Compatibility.)

Rate of Administration

Direct IV injection: Usually, very slowly, preferably as a 10-mg/mL injection.^{246 HID}

IV injection for PCA: Self-administered intermittently as needed (“prn”) via controlled-delivery device, with usual lockout intervals (minimum time between self-administered doses programmed into device) of 6–12 minutes.²⁴⁶

IV infusion, adults: Usually, 15–35 mg/hour.^b

IM Administration

Inject into a large muscle mass, taking care to avoid nerve trunks.^b

IM injection is discouraged for any analgesic (e.g., the injection itself is painful, delayed onset).^{246 247 248}

When repeat parenteral doses are necessary and IV therapy is not used, IM is preferred over sub-Q administration because of occurrence of local tissue irritation and induration following sub-Q injection.^b

Epidural Administration

Preservative-free injections have been injected or infused epidurally†; specialized techniques are required for administration of the drug by this route, and such administration should be performed only by qualified individuals familiar with the techniques of administration, dosages, and special patient management problems associated with epidural meperidine hydrochloride administration.^b

Dosage

Pediatric Patients

Some experts discourage use in children.²⁴⁵

Usual Dosage

Oral, IM, or Sub-Q

May receive 1.1–1.8 mg/kg (up to adult dose) orally, IM, or sub-Q every 3–4 hours as needed.^{b c 246}

Alternatively, 175 mg/m² daily in 6 divided doses orally, IM, or sub-Q.^b

Single pediatric doses should not exceed 100 mg.^b

IV

Do not use for PCA when analgesic consumption is expected to be high; risk of CNS excitatory toxicity from normeperidine.²⁴⁷

PCA (usually IV) via controlled-delivery device: Loading doses of 0.5–1.5 mg/kg, preferably titrated by clinician or nurse at bedside.²⁴⁶

PCA (usually IV) via controlled-delivery device: Maintenance doses (administered intermittently) of 0.1–0.2 mg/kg, self-administered usually no more frequently than every 6–12 minutes as a device-programmed lockout period.²⁴⁶

Preoperative Dosage

IM or Sub-Q

May receive 1–2.2 mg/kg (maximum up to the adult dose) IM or sub-Q 30–90 minutes before the beginning of anesthesia.^b

Adjunct to Anesthesia

IV Injection or IV Infusion

May be given by repeated slow IV injections of a dilute solution (e.g., containing 10 mg/mL) or by continuous IV infusion of a more dilute solution (e.g., containing 1 mg/mL).^b

Adults

Usual Dosage

Oral, IM, or Sub-Q

Usually, 50–150 mg every 3–4 hours as needed.^{b c 246}

IV infusion

Usually, 15–35 mg/hour.^b

IV

Do not use for PCA when analgesic consumption is expected to be high; risk of CNS excitatory toxicity from normeperidine.²⁴⁷

PCA (usually IV) via controlled-delivery device: Loading doses of 12.5–25 mg every 10 minutes, preferably titrated by clinician or nurse at bedside, up to 50–125 mg total.²⁴⁶

PCA (usually IV) via controlled-delivery device: Maintenance doses (self-administered intermittently) of 5–10 mg, self-administered usually no more frequently than every 6–12 minutes as a device-programmed lockout period.²⁴⁶

Preoperative Dosage

IM or Sub-Q

Usually, 50–100 mg IM or sub-Q 30–90 minutes before the beginning of anesthesia.^b

Adjunct to Anesthesia

IV Injection or IV Infusion

May be given by repeated slow IV injections of a dilute solution (e.g., containing 10 mg/mL) or by continuous IV infusion of a more dilute solution (e.g., containing 1 mg/mL).^b

Analgesia during Labor

IM or Sub-Q

50–100 mg when labor pains become regular; repeat at 1- to 3-hour intervals as needed.^b

Prescribing Limits

Pediatric Patients

Oral, IM, or Sub-Q

Single pediatric doses should not exceed 100 mg.^b

Adults

Oral, IV, IM, or Sub-Q

Increased risk of toxicity from the active metabolite, normeperidine, when given for >48 hours or in total dosages exceeding 600 mg/24 hours.²⁴⁵ (See Elimination under Pharmacokinetics.)

Special Populations

Hepatic Impairment

Adjustment in the dose, frequency, and/or duration of therapy may be necessary because accumulation of the drug and/or its toxic metabolite, normeperidine, can occur.^{200 204 205 206 207 208 209 210 211 212 213}

Certain adverse effects secondary to CNS stimulation (e.g., seizures, agitation, irritability, nervousness, tremors, twitches, myoclonus) have been attributed to accumulation of normeperidine.^{200 201 204 205 206 209 210 211 240}

Oral bioavailability may be increased substantially in these patients.^{212 213} (See Pharmacokinetics.)

Renal Impairment

Generally avoid in renal impairment, particularly repeated or high doses.^{246 247 245}

If used, adjustment in the dose, frequency, and/or duration of meperidine therapy is likely to be necessary because accumulation of the drug and/or its toxic metabolite, normeperidine, can occur.^{200 204 205 206 207 208 209 210 211 212 213}

Certain adverse effects secondary to CNS stimulation (e.g., seizures, agitation, irritability, nervousness, tremors, twitches, myoclonus) have been attributed to accumulation of normeperidine.^{200 201 204 205 206 209 210 211 240}

End-stage Renal Failure

Avoid because of the risk of accumulation of the toxic metabolite, normeperidine.^{200 205 207 208 211 220}

Cautions for Demerol

Contraindications

• 
  

  Patients receiving MAO inhibitors.^{b e 244}

  
  


• 
  

  Known hypersensitivity to meperidine or any ingredient in the respective formulation.²⁴⁴

  
  

Warnings/Precautions

Warnings

Shares the toxic potentials of the opiate agonists; observe the usual precautions of opiate agonist therapy.^e

Serotonin Syndrome

Serotonin syndrome may occur in patients receiving MAO inhibitors in conjunction with other serotonergic drugs, including meperidine.

Concomitant use with an MAO inhibitor has resulted in excitatory effects (e.g., agitation, bizarre behavior, headache, hypertension, hypotension, rigidity, seizures, hyperpyrexia, coma) associated with serotonin syndrome.

Concomitant Use of Other CNS Depressants

Additive depressant effects may occur with concomitant use of other CNS depressants including other opiates, sedatives or hypnotics, general anesthetics, phenothiazines, tranquilizers, skeletal muscle relaxants, sedating antihistamines, and alcohol.^{e 244}

When such combined therapy is contemplated, the dose of one or both agents should be reduced.^b

Respiratory Depression

Causes dose-related respiratory depression.^{e 244}

Respiratory depression is most common in geriatric or debilitated patients, or in conditions accompanied by hypoxia or hypercapnia; even moderate therapeutic opiate dosages may dangerously decrease pulmonary ventilation.^{e 244}

Use with extreme caution, if at all, in anoxia, hypercapnia, respiratory depression, or in those who are especially prone to respiratory depression such as comatose patients or those with head injury, brain tumor, or elevated CSF pressure.^e

Also use with extreme caution, if at all, in cor pulmonale, acute asthma exacerbation, or COPD and in others with substantially decreased respiratory reserve as in emphysema, hypoxia, hypercapnia, kyphoscoliosis, or severe obesity.^{e 244}

Head Injury and Increased Intracranial Pressure

Respiratory depression effects and ability of opiates to increase CSF pressure may be markedly exaggerated in patients with head injury, other intracranial lesions, or preexisting elevation in intracranial pressure; opiate effects may produce cerebral hypoxia and obscure clinical course of patients with head injuries.²⁴⁴ Use with extreme caution, if at all.²⁴⁴

May interfere with evaluation of CNS function, and respiratory depression produced by the drug may produce cerebral hypoxia and elevated CSF pressure not caused by the injury itself.^{e 246}

Ambulatory Patients

Performance of activities requiring mental alertness and physical coordination may be impaired (e.g., operating a motor vehicle or machinery).²⁴⁴

Hypotension

May cause severe hypotension postoperatively or when ability to maintain blood pressure is compromised (e.g., depleted blood volume, concurrent phenothiazine or general anesthetic use).²⁴⁴

May produce orthostatic hypotension in amubulatory patients.²⁴⁴

IM injection

Inadvertent IM injection into or near nerve trunks can result in sensory-motor paralysis, which may or may not be transient.^b

Dependence

Physical and psychic dependence and tolerance may develop with repeated administration, and abuse potential exists; use with caution.^e

Sensitivity Reactions

Sulfite Sensitivity

Some commercially available formulations contain sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylaxis and life-threatening or less severe asthmatic episodes, in certain susceptible individuals.^b

Overall prevalence of sulfite sensitivity in the general population is unknown but probably low; such sensitivity appears to occur more frequently in asthmatic than in nonasthmatic individuals.^b

General Precautions

Toxic Psychosis and Special Populations

Care should be exercised and the initial dosage of the opiate agonist should be reduced in patients with toxic psychosis and in geriatric or debilitated patients.^e

Cardiac Arrhythmias

May increase ventricular response rate through a vagolytic action, therefore use with caution in patients with atrial flutter and other supraventricular tachycardias.^{b 244}

Acute Abdominal Conditions

May obscure diagnosis or clinical course of patients with acute abdominal conditions.²⁴⁴

Seizure Risk

May aggravate preexisting seizure disorders.

Accumulation of toxic normeperidine metabolite can stimulate the CNS and precipitate seizures in patients without a preexisting seizure disorder.^{246 247 245 248}

Normeperidine Accumulation

Use with caution in patients at risk for accumulation of normeperidine (e.g., those with renal or hepatic impairment) and during prolonged therapy and/or with high dosages in other patients (e.g., those with sickle cell anemia or CNS disease, burn patients, cancer patients) at risk for neurotoxic effects of the metabolite.^{200 204 205 206 207 208 209 210 211 212 213 220 240 245}

Observe these patients closely for potential manifestations of CNS stimulation (e.g., seizures, agitation, irritability, nervousness, tremors, twitches, myoclonus) associated with accumulation of the metabolite.^{246 247 248 200 204 205 206 208 209 210 211 220 240}

Specific Populations

Pregnancy

Category C.^PDH

Lactation

Distributed into milk.^{246 244} Discontinue nursing or the drug.²⁴⁴

Pediatric Use

Should not be given to infants <6 months of age;^PDH neonatal elimination is greatly reduced.²⁴⁶

Some experts discourage use in children of any age.²⁴⁵

Geriatric Use

Elimination is slower in geriatric patients than in younger patients.²⁴⁴

Geriatric patients, especially those with decreased renal and hepatic function, may be at greater risk for adverse CNS effects secondary to accumulation of the toxic metabolite normeperidine.^{242 243 244}

Use with caution in geriatric patients, taking into account the potential risks and benefits to the patient, and dosage adjustment should be considered.^{246 242 243 244}

Hepatic Impairment

Adjustment in the dose, frequency, and/or duration of therapy may be necessary because accumulation of the drug and/or its toxic metabolite, normeperidine, can occur.^{200 204 205 206 207 208 209 210 211 212 213} (See Hepatic Impariment under Dosage and Administration.)

Renal Impairment

Generally avoid in renal impairment, particularly repeated or high doses.^{246 247 245} (See Renal Impariment under Dosage and Administration.)

Common Adverse Effects

Adverse CNS effects include dizziness, visual disturbances, mental clouding or depression, sedation, coma, euphoria, dysphoria, weakness, faintness, agitation, restlessness, nervousness, seizures, and, rarely, delirium and insomnia.^e

Adverse GI effects of opiate agonists include nausea, vomiting, and constipation.^e

Opiate agonists may interfere with evaluation of CNS function, especially relative to consciousness levels, pupillary changes, and respiratory depression, thereby masking the patient’s clinical course.^e

May increase the risk of water intoxication in postoperative patients because of stimulation of the release of vasopressin.^e

Interactions for Demerol

Specific Drugs

Drug	Interaction	Comments
Amphetamines	Dextroamphetamine may enhance opiate agonist analgesiae	May be used to therapeutic advantage
Anticoagulants	Opiate agonists have been reported to potentiate the anticoagulant activity of coumarin anticoagulantse
Antidepressants, tricyclic	May potentiate the effects of tricyclic antidepressants e	Use concomitantly with caution; dosage adjustment may be necessarye
CNS depressants	May potentiate the effects of other CNS depressants including other opiates, general anesthetics, tranquilizers, sedatives and hypnotics, and alcohole	Use with great caution and in reduced dosage when used in conjunction with such drugs; some tranquilizers, especially phenothiazines, may antagonize opiate agonist analgesiae
Diuretics	Opiate agonists may decrease the effects of diuretics in patients with congestive heart failuree
Estrogens or estrogen-progestin combinations (oral contraceptives)	Oral contraceptives or estrogens may inhibit meperidine metabolism; clinical importance of this inhibition on analgesic effectiveness of meperidine has not been determinedb
Isoniazid	Concomitant use may aggravate the adverse effects of isoniazidb
MAO inhibitors	Therapeutic doses of meperidine concomitantly with an MAO inhibitor have produced coma, severe respiratory depression, cyanosis, and hypotension resembling the typical syndrome of acute opiate overdosage; these adverse effects may be associated with preexisting hyperphenylalaninemiab Also, hyperexcitability and hypertension with concomitant useb	Meperidine is contraindicated in patients who have received an MAO inhibitor during the previous 14 daysb e
Skeletal muscle relaxants	May enhance the neuromuscular blocking action of skeletal muscle relaxantse

Demerol Pharmacokinetics

Absorption

Bioavailability

Oral: Undergoes extensive first-pass metabolism in the liver, with approximately 50–60% of a dose reaching systemic circulation unchanged.^{246 246 207 212 213 214}

Oral: Bioavailability increases to approximately 80–90% in patients with hepatic impairment.^{212 213}

Less than half as effective when given orally as when given parenterally.^{b 247}

IM: Approximately 80–85% of a dose of the drug is absorbed within 6 hours after intragluteal injection.²¹⁷

Onset

Oral, peak analgesia: Within 1 hour and declines gradually over 2–4 hours.^b

Sub-Q, peak analgesia: In about 40–60.^b

IM, peak analgesia: In about 30–50 minutes.^b

Duration

Sub-Q or IM: Analgesia is maintained for 2–4 hours.^b

Plasma Concentrations

Oral, peak: About 1 hour.²⁴⁶

IM, peak: Within 5–15 minutes..²⁴⁶

Distribution

Extent

Crosses the placenta; may accumulate in fetus.^{246 207 218}

Distributes into breast milk.^{b 244}

Plasma Protein Binding

Approximately 60–80%;^{246 212} principally albumin and α₁-acid glycoprotein.^{246 212}

Elimination

Metabolism

Principally in the liver.^{b 246}

Normeperidine is the active metabolite and exhibits about half the analgesic potency of meperidine but twice the CNS stimulant (e.g., seizure-inducing) potency.^{200 201 202 203 204 205 206 207 208 209 210 211}

Various toxic effects secondary to CNS stimulation (e.g., seizures, agitation, irritability, nervousness, tremors, twitches, myoclonus) have been attributed to accumulation of normeperidine.^{200 201 204 205 206 209 210 211 240}

Elimination Route

Excreted in urine as metabolites and unchanged drug.^{b 246}

Acidifying the urine enhances excretion of the unchanged drug and normeperidine.^b

Half-life

Distribution phase half-life, meperidine: 2–11 minutes^{207 215 219}

Terminal elimination half-life, meperidine: 3–5 hours.^{246 200 204 205 207 213 214 215 216 217 219}

Terminal elimination half-life, normeperidine: Approximately 8–21 hours.^{246 200 204 205 207 208 210}

Special Populations

Elimination half-life in hepatic dysfunction, meperidine: Prolonged.²⁰⁷

Cirrhosis^{207 213 215} or active viral hepatitis:^{207 216} Averages about 7–11 hours.^b

Terminal elimination half-life in renal impairment, normeperidine: May be prolonged (e.g., 30–40 hours).^{200 204 205 207 208 210 211}

Renal or hepatic impairment: Accumulation of normeperidine may occur with repeated, high doses of the drug.^{200 204 205 206 207 212 213 240}

Stability

Storage

Protect from light and store at a temperature <40°C.^b

Oral

Tablets

Well-closed containers^b at 25°C (may be exposed to 15–30°C).²⁴⁴

Oral Solution

Tight containers^b at 25°C (may be exposed to 15–30°C).²⁴⁴

Avoid freezing.^b

Parenteral

Injection

15–25°C.^b

Avoid freezing.^b

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution Compatibility^HID

Compatible
Dextran 6% in dextrose 5%
Dextran 6% in sodium chloride 0.9%
Dextrose–Ringer’s injection combinations
Dextrose–Ringer’s injection, lactated, combinations
Dextrose–saline combinations
Dextrose 2½, 4, 5, or 10% in water
Fructose 10% in sodium chloride 0.9%
Fructose 10% in water
Invert sugar 5 and 10% in sodium chloride 0.9%
Invert sugar 5 and 10% in water
Ionosol products
Ringer’s injection
Ringer’s injection, lactated
Sodium chloride 0.18, 0.45, or 0.9%
Sodium lactate (1/6) M

Drug Compatibility

Admixture CompatibilityHID

Compatible
Cefazolin sodium
Dobutamine HCl
Metoclopramide HCl
Ondansetron HCl
Scopolamine HBr
Succinylcholine chloride
Verapamil HCl
Incompatible
Aminophylline
Amobarbital sodium
Furosemide
Heparin sodium
Morphine sulfate
Phenobarbital sodium
Phenytoin sodium
Thiopental sodium
Variable
Sodium bicarbonate

Y-Site CompatibilityHID

Compatible
Amifostine
Amikacin sulfate
Ampicillin sodium
Ampicillin sodium–sulbactam sodium
Atenolol
Aztreonam
Bivalirudin
Bumetanide
Cefazolin sodium
Cefotaxime sodium
Cefoxitin sodium
Ceftazidime
Ceftizoxime sodium
Ceftriaxone sodium
Cefuroxime sodium
Chloramphenicol sodium succinate
Cladribine
Clindamycin phosphate
Co-trimoxazole
Dexamethasone sodium phosphate
Dexmedetomidine HCl
Digoxin
Diltiazem HCl
Diphenhydramine HCl
Dobutamine HCl
Docetaxel
Dopamine HCl
Doxycycline hyclate
Droperidol
Erythromycin lactobionate
Etoposide phosphate
Famotidine
Fenoldopam mesylate
Filgrastim
Fluconazole
Fludarabine phosphate
Gallium nitrate
Gemcitabine HCl
Gentamicin sulfate
Granisetron HCl
Heparin sodium
Hetastarch in lactated electrolyte injection (Hextend)
Hydrocortisone sodium succinate
Kanamycin sulfate
Labetalol HCl
Lidocaine HCl
Linezolid
Magnesium sulfate
Melphalan HCl
Methyldopate HCl
Methylprednisolone sodium succinate
Metoclopramide HCl
Metoprolol tartrate
Metronidazole
Ondansetron HCl
Oxacillin sodium
Oxytocin
Oxaliplatin
Paclitaxel
Pemetrexed disodium
Penicillin G potassium
Piperacillin sodium–tazobactam sodium
Potassium chloride
Propofol
Propranolol HCl
Ranitidine HCl
Remifentanil HCl
Sargramostim
Teniposide
Thiotepa
Ticarcillin disodium–clavulanate potassium
Tobramycin sulfate
Vancomycin HCl
Verapamil HCl
Vinorelbine tartrate
Incompatible
Allopurinol sodium
Amphotericin B cholesteryl sulfate complex
Cefepime HCl
Doxorubicin HCl liposome injection
Idarubicin HCl
Imipenem–cilastatin sodium
Lansoprazole
Variable
Acyclovir sodium
Furosemide
Nafcillin sodium

ActionsActions

• 
  

  Opiate agonists alter perception of and emotional response to pain.²⁴⁶

  
  


• 
  

  Precise mechanism of action has not been fully elucidated; opiate agonists act at several CNS sites, involving several neurotransmitter systems to produce analgesia.²⁴⁶

  
  


• 
  

  Pain perception is altered in the spinal cord and higher CNS levels (e.g., substantia gelatinosa, spinal trigeminal nucleus, periaqueductal gray, periventricular gray, medullary raphe nuclei, hypothalamus).²⁴⁶

  
  


• 
  

  Opiate agonists do not alter the threshold or responsiveness of afferent nerve endings to noxious stimuli, nor peripheral nerve impulse conduction.²⁴⁶

  
  


• 
  

  Opiate agonists act at specific receptor binding sites in the CNS and other tissues; opiate receptors are concentrated in the limbic system, thalamus, striatum, hypothalamus, midbrain, and spinal cord.²⁴⁶

  
  


• 
  

  Agonist activity at the opiate μ- or κ-receptor can result in analgesia, miosis, and/or decreased body temperature.²⁴⁶

  
  


• 
  

  Agonist activity at the μ-receptor can also result in suppression of opiate withdrawal (and antagonist activity can result in precipitation of withdrawal).²⁴⁶

  
  


• 
  

  Respiratory depression may be mediated by μ-receptors, possibly μ₂-receptors (which may be distinct from μ₁-receptors involved in analgesia); κ- and δ-receptors may also be involved in respiratory depression.²⁴⁶

  
  


• 
  

  Equianalgesic doses of meperidine hydrochloride and morphine sulfate produce the same degree of respiratory depression.^b

  
  


• 
  

  Sedative and euphoric effects of equianalgesic doses of meperidine may be greater than those of morphine but reports are conflicting.^b

  
  


• 
  

  Causes little or no constipation and has antitussive activity only in analgesic doses.^b

  
  


• 
  

  Exhibits some anticholinergic properties.^e

  
  


• 
  

  Systemic administration: May cause corneal anesthesia which can abolish the corneal reflex.^b

  
  


• 
  

  Topical application: Produces considerable local anesthesia, but meperidine is not utilized for local anesthesia because it also produces local irritation.^b

  
  


• 
  

  Overdosage may produce mydriasis rather than miosis.^e

  
  


• 
  

  Toxic effects may be excitatory.^e

  
  

Advice to Patients

• 
  

  Potential for drug to impair mental alertness or physical coordination; avoid driving or operating machinery until effects on individual are known.²⁴⁴

  
  


• 
  

  Advise patients of risk of postural hypotension during ambulation.²⁴⁴

  
  


• 
  

  Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.

  
  


• 
  

  Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.

  
  


• 
  

  Importance of informing patients of other important precautionary information. (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Meperidine hydrochloride preparations are subject to control under the Federal Controlled Substances Act of 1970 as schedule II (C-II) drugs.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Meperidine Hydrochloride

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Solution	50 mg/5 mL*	Demerol Hydrochloride Syrup ( C-II)	Sanofi-Aventis
			Meperidine HCl Syrup ( C-II)	Roxane
	Tablets	50 mg*	Demerol Hydrochloride ( C-II)	Sanofi-Aventis
		100 mg*	Demerol Hydrochloride ( C-II)	Sanofi-Aventis
Parenteral	Injection	25 mg/mL*	Demerol Hydrochloride ( C-II; preservative-free in Carpuject cartridges)	Hospira
			Meperidine HCl Injection ( C-II; preservative-free in ampuls and Tubex)	Baxter
		50 mg/mL*	Demerol Hydrochloride ( C-II; preservative-free in ampuls and Carpuject cartridges or with metacresol 0.1% in multiple-dose vials)	Hospira
			Meperidine HCl Injection ( C-II; with metacresol)	AstraZeneca
			Meperidine HCl Injection ( C-II; preservative-free in ampuls and Tubex or with phenol and sodium metabisulfite in multiple-dose vials)	Baxter
		75 mg/mL*	Demerol Hydrochloride ( C-II; preservative-free in Carpuject cartridges)	Hospira
			Meperidine HCl Injection ( C-II; preservative-free in ampuls and Tubex)	Baxter
		100 mg/mL*	Demerol Hydrochloride ( C-II; preservative-free in ampuls and Carpuject cartridges or with metacresol 0.1% in multiple-dose vials)	Hospira
			Meperidine HCl Injection ( C-II; with metacresol)	AstraZeneca
			Meperidine HCl Injection ( C-II; preservative-free in ampuls and Tubex or with phenol and sodium metabisulfite in multiple-dose vials)	Baxter
	Injection, for IV infusion via compatible infusion devices only	10 mg/mL (300 mg)*	Meperidine HCl Injection ( C-II; preservative-free)	Hospira

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pr

Alendroninezuur Bentley

Alendroninezuur Bentley may be available in the countries listed below.

Ingredient matches for Alendroninezuur Bentley

Alendronic Acid

Alendronic Acid sodium trihydrate (a derivative of Alendronic Acid) is reported as an ingredient of Alendroninezuur Bentley in the following countries:

• Netherlands

International Drug Name Search

Mébendazole

Mébendazole may be available in the countries listed below.

Ingredient matches for Mébendazole

Mebendazole

Mébendazole (DCF) is known as Mebendazole in the US.

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Pronivel

Pronivel may be available in the countries listed below.

Ingredient matches for Pronivel

Erythropoietin

Erythropoietin is reported as an ingredient of Pronivel in the following countries:

• Argentina

International Drug Name Search

Beclometasone Dipropionate

Beclometasone Dipropionate may be available in the countries listed below.

Ingredient matches for Beclometasone Dipropionate

Beclometasone

Beclometasone Dipropionate (BANM) is also known as Beclometasone (Rec.INN)

International Drug Name Search

Glossary

BANM	British Approved Name (Modified)
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Disys Plus

Disys Plus may be available in the countries listed below.

Ingredient matches for Disys Plus

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Disys Plus in the following countries:

• Bangladesh

Valsartan

Valsartan is reported as an ingredient of Disys Plus in the following countries:

• Bangladesh

International Drug Name Search

Dextrose and Electrolyte No 48

Dosage Form: injection

in VIAFLEX Plastic Container

Dextrose and Electrolyte No 48 Description

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container for intravenous administration. Each 100 mL contains 5 g Dextrose Hydrous, USP*, 260 mg Sodium Lactate (C3H5NaO3), 141 mg Potassium Chloride, USP (KCl), 31 mg Magnesium Chloride, USP (MgCl2•6H20), 20 mg Monobasic Potassium Phosphate, NF (KH2PO4), and 12 mg Sodium Chloride, USP (NaCl). It contains no antimicrobial agents. pH 5.0 (4.0 to 6.5).

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) administered intravenously has value as a source of water, electrolytes, and calories. One liter has an ionic concentration of 25 mEq sodium, 20 mEq potassium, 3 mEq magnesium, 24 mEq chloride, 23 mEq lactate and 3 mEq phosphate as HPO4=. The osmolarity is 348 mOsmol/L (calc). Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions (≥ 600 mOsmol/L) may cause vein damage. The caloric content is 180 kcal/L.

The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.

Dextrose and Electrolyte No 48 - Clinical Pharmacology

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) has value as a source of water, electrolytes and calories. They are capable of inducing diuresis depending on the clinical condition of the patient.

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) produce a metabolic alkalinizing effect. Lactate ions are metabolized ultimately to carbon dioxide and water, which requires the consumption of hydrogen cations.

Indications and Usage for Dextrose and Electrolyte No 48

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is indicated as a source of water, electrolytes, and calories or as an alkalinizing agent.

Contraindications

Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

Warnings

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention.

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with great care in patients with metabolic or respiratory alkalosis. The administration of lactate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe hepatic insufficiency.

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should not be administered simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or hemolysis.

The intravenous administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injection. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injection.

In patients with diminished renal function, administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may result in sodium or potassium retention.

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is not for use in the treatment of lactic acidosis.

Precautions

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with caution. Excess administration may result in metabolic alkalosis.

Caution must be exercised in the administration of these injections to patients receiving corticosteroids or corticotropin.

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with caution in patients with overt or subclinical diabetes mellitus.

Pregnancy

Teratogenic Effects

Pregnancy Category C

Animal reproduction studies have not been conducted with 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP). It is also not known whether 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be given to a pregnant woman only if clearly needed.

Pediatric Use

Safety and effectiveness of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in pediatric patients have not been established by adequate and well controlled trials, however, the use of dextrose and electrolytes solutions in the pediatric population is referenced in the medical literature. The warnings, precautions and adverse reactions identified in the label copy should be observed in the pediatric population.

In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible hemorrhage.

Geriatric Use

Clinical studies of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Carcinogenesis and Mutagenesis and Impairment of Fertility

Studies with 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is administered to a nursing mother.

Do not administer simultaneously with blood. Do not administer unless solution is clear and seal is intact.

Adverse Reactions

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

Dextrose and Electrolyte No 48 Dosage and Administration

As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile equipment.

As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low weight infants, because of the increased risk of hyperglycemia/hypoglycemia.

Additives may be incompatible. Complete information is not available.

Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.

How is Dextrose and Electrolyte No 48 Supplied

5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in VIAFLEX plastic containers is available as shown below:

Code	Size (mL)	NDC
2B2102	250	NDC 0338-0143-02
2B2103	500	NDC 0338-0143-03
2B2104	1000	NDC 0338-0143-04

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.

DIRECTIONS FOR USE OF VIAFLEX PLASTIC CONTAINERS

Warning: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn in from the primary container before administration of the fluid from the secondary container is completed.

To Open

Tear overwrap down side at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below.

Preparation for Administration

1. Suspend container from eyelet support.

2. Remove plastic protector from outlet port at bottom of container.

3. Attach administration set. Refer to complete directions accompanying set.

To Add Medication

Warning: Additives may be incompatible.

To add medication before solution administration

1. Prepare medication site.

2. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.

3. Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.

To add medication during solution administration

1. Close clamp on the set.

2. Prepare medication site.

3. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.

4. Remove container from IV pole and/or turn to an upright position.

5. Evacuate both ports by squeezing them while container is in the upright position.

6. Mix solution and medication thoroughly.

7. Return container to in use position and continue administration.

Baxter Healthcare Corporation

Deerfield, IL 60015 USA

Printed in USA

071947768

07-19-47-768 June 2005

BAXTER, VIAFLEX and PL 146 are trademarks of Baxter International Inc

DEXTROSE AND ELECTROLYTE NO. 48  sodium lactate, potassium chloride, magnesium chloride, monobasic potassium phosphate, sodium chloride and dextrose monohydrate  injection, solution

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 0338-0143 Route of Administration INTRAVENOUS DEA Schedule

INGREDIENTS Name (Active Moiety) Type Strength Dextrose monohydrate (Dextrose) Active 5 GRAM  In 100 MILLILITER Sodium Lactate (Sodium Lactate) Active 260 MILLIGRAM  In 100 MILLILITER Potassium Chloride (Potassium Chloride) Active 141 MILLIGRAM  In 100 MILLILITER Magnesium Chloride (Magnesium Chloride) Active 31 MILLIGRAM  In 100 MILLILITER Monobasic Potassium Phosphate (Monobasic Potassium Phosphate) Active 20 MILLIGRAM  In 100 MILLILITER Sodium Chloride (Sodium Chloride) Active 12 MILLIGRAM  In 100 MILLILITER Water Inactive

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 0338-0143-02 250 mL (MILLILITER) In 1 BAG None 2 0338-0143-03 500 mL (MILLILITER) In 1 BAG None 3 0338-0143-04 1000 mL (MILLILITER) In 1 BAG None

Revised: 05/2007Baxter Healthcare Corporation

More Dextrose and Electrolyte No 48 resources

• Dextrose and Electrolyte No 48 Drug Interactions
• Dextrose and Electrolyte No 48 Support Group
• 0 Reviews · Be the first to review/rate this drug

Diabetic Ketoacidosis, in DM Type II Medications

There are currently no drugs listed for "Diabetic Ketoacidosis, in DM Type II".

Definition of Diabetic Ketoacidosis, in DM Type II: Diabetic ketoacidosis (DKA) is a serious complication of diabetes mellitus (DM), or diabetes. It may occur in some people when their diabetes is not well controlled.

Learn more about Diabetic Ketoacidosis, in DM Type II

Micromedex Care Notes:

• Diabetic Ketoacidosis
• Diabetic Ketoacidosis In Children

Medical Encyclopedia:

• Diabetic ketoacidosis

Drug List:

Innosensitive

Innosensitive may be available in the countries listed below.

Ingredient matches for Innosensitive

Alfuzosin

Alfuzosin hydrochloride (a derivative of Alfuzosin) is reported as an ingredient of Innosensitive in the following countries:

• Greece

International Drug Name Search

Delipid

Delipid may be available in the countries listed below.

Ingredient matches for Delipid

Gemfibrozil

Gemfibrozil is reported as an ingredient of Delipid in the following countries:

• Bangladesh

International Drug Name Search

Regel-SO

Regel-SO may be available in the countries listed below.

Ingredient matches for Regel-SO

Oxetacaine

Oxetacaine is reported as an ingredient of Regel-SO in the following countries:

• India

Sucralfate

Sucralfate is reported as an ingredient of Regel-SO in the following countries:

• India

International Drug Name Search

Balsalazide

In the US, Balsalazide (balsalazide systemic) is a member of the drug class 5-aminosalicylates and is used to treat Crohn's Disease, Ulcerative Colitis and Ulcerative Colitis - Active.

US matches:

• Balsalazide


• Balsalazide Disodium

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A07EC04

CAS registry number (Chemical Abstracts Service)

0080573-04-2

Chemical Formula

C17-H15-N3-O6

Molecular Weight

357

Therapeutic Categories

Anti-inflammatory agent

Gastrointestinal agent

Chemical Names

(E)-5-[[p-[(2-Carboxyethyl)carbamoyl]phenyl]azo]salicylic acid (WHO)

Benzoic acid, 5-[[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]azo]-2-hydroxy-, (E)-

Foreign Names

• Balsalazidum (Latin)
• Balsalazid (German)
• Balsalazide (French)
• Balsalazida (Spanish)

Generic Names

• Balsalazide (OS: BAN, DCF)
• BX 661 A (IS: Biorex)
• Mesalamine (5-aminosalicylic acid 5-ASA), Prodrug of (IS)
• Prodrug of Mesalamine (IS: 5-aminosalicylic acid 5-ASA)
• Balsalazide Disodium (OS: USAN)
• Balsalazide Sodium (OS: BANM)

Brand Names

• Balsalazida
  Monte, Argentina



• Benoquin
  Ivax, Argentina



• Colazide
  Pharmatel, Australia



• Intazide
  Intas, India



• Balsalazide Disodium
  Apotex, United States; Mylan, United States; Roxane, United States



• Balzide
  Menarini, Italy



• Basazyde
  Lotus, Taiwan



• Colazal
  Salix, United States



• Colazid
  Meda, Sweden; Shire, Norway



• Colazide
  Almirall, United Kingdom



• Premid
  Almirall, Denmark

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
DCF	Dénomination Commune Française
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Hydrazide

Hydrazide may be available in the countries listed below.

Ingredient matches for Hydrazide

Isoniazid

Isoniazid is reported as an ingredient of Hydrazide in the following countries:

• Japan

International Drug Name Search

Semprex-D

Semprex-D is a brand name of acrivastine/pseudoephedrine, approved by the FDA in the following formulation(s):

SEMPREX-D (acrivastine; pseudoephedrine hydrochloride - capsule; oral)

• 
  Manufacturer: UCB INC
  
  Approval date: March 25, 1994
  
  Strength(s): 8MG;60MG ^[RLD]

Has a generic version of Semprex-D been approved?

No. There is currently no therapeutically equivalent version of Semprex-D available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Semprex-D. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Semprex-D.

See also...

• Semprex-D Consumer Information (Wolters Kluwer)
• Semprex-D Consumer Information (Cerner Multum)
• Acrivastine/Pseudoephedrine Consumer Information (Wolters Kluwer)
• Acrivastine and pseudoephedrine Consumer Information (Cerner Multum)

Deltacal

Deltacal may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Deltacal

Calcium Carbonate

Calcium Carbonate is reported as an ingredient of Deltacal in the following countries:

• Australia

International Drug Name Search

Zorclone

Zorclone may be available in the countries listed below.

Ingredient matches for Zorclone

Eszopiclone

Zopiclone is reported as an ingredient of Zorclone in the following countries:

• Ireland

International Drug Name Search

Slo-Niacin

In the US, Slo-Niacin (niacin systemic) is a member of the following drug classes: miscellaneous antihyperlipidemic agents, vitamins and is used to treat High Cholesterol, Hyperlipoproteinemia, Hyperlipoproteinemia Type IV - Elevated VLDL, Hyperlipoproteinemia Type V - Elevated Chylomicrons VLDL, Niacin Deficiency and Pellagra.

US matches:

• Slo-Niacin Controlled-Release Capsules


• Slo-Niacin nicotinic acid


• Slo-Niacin

Ingredient matches for Slo-Niacin

Nicotinic Acid

Nicotinic Acid is reported as an ingredient of Slo-Niacin in the following countries:

• United States

International Drug Name Search

Disofrol

Disofrol may be available in the countries listed below.

Ingredient matches for Disofrol

Dexbrompheniramine

Dexbrompheniramine maleate (a derivative of Dexbrompheniramine) is reported as an ingredient of Disofrol in the following countries:

• Spain


• Sweden


• Switzerland

Pseudoephedrine

Pseudoephedrine sulfate (a derivative of Pseudoephedrine) is reported as an ingredient of Disofrol in the following countries:

• Spain


• Sweden


• Switzerland

International Drug Name Search